Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | NOS2 | P35228 | 4/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480040 | 0.84 | NAPRT (0.55) | NOS3NOS2TDP1KDM4EL3MBTL1 | |
| SCHEMBL353138 | 0.82 | SIRT3 (0.46) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| SCHEMBL19439221 | 0.80 | SIRT3 (0.44) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5796678 | 0.80 | SIRT3 (0.44) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| SCHEMBL3553958 | 0.79 | KDM4E (0.53) | NOS3NOS2KDM4EMAPT | |
| SCHEMBL21248760 | 0.79 | NOS3 (0.45) | NOS3NOS2PIK3CBSIRT3TDP1 | |
| SCHEMBL15991433 | 0.78 | SIRT3 (0.43) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| SCHEMBL16447580 | 0.78 | SIRT3 (0.43) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| SCHEMBL27675661 | 0.78 | SIRT3 (0.43) | PIK3CBSIRT3TDP1KDM4EL3MBTL1 | |
| SCHEMBL31661247 | 0.78 | NOS2 (0.46) | NOS3NOS2PIK3CBNAPRTNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3066092-B1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3066092-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | disclosed |
| CN-105849097-A | Substituted pyridine derivatives as GSK-3 inhibitors | 百时美施贵宝公司 | 2016-08-10 | — | — | CN | disclosed |
| WO-2015069593-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-1697308-A4 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1697308-A2 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005065195-A2 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | GSK3B, GSK3A, GRIN3A | NOS3 2012/4885NOS2 4047/4885PIK3CB 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.